RU2013133813A - Средства для выведения биомолекул из кровотока - Google Patents
Средства для выведения биомолекул из кровотока Download PDFInfo
- Publication number
- RU2013133813A RU2013133813A RU2013133813/15A RU2013133813A RU2013133813A RU 2013133813 A RU2013133813 A RU 2013133813A RU 2013133813/15 A RU2013133813/15 A RU 2013133813/15A RU 2013133813 A RU2013133813 A RU 2013133813A RU 2013133813 A RU2013133813 A RU 2013133813A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- aryl
- group
- independently
- agent
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims abstract 77
- 125000003118 aryl group Chemical group 0.000 claims abstract 73
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 29
- 125000001424 substituent group Chemical group 0.000 claims abstract 10
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 239000008280 blood Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims abstract 2
- 125000002897 diene group Chemical group 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 21
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 150000002402 hexoses Chemical class 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 150000001721 carbon Chemical class 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- -1 4-pyrimidyl Chemical group 0.000 claims 3
- 150000001993 dienes Chemical class 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000008685 targeting Effects 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 125000006575 electron-withdrawing group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical group 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241001168730 Simo Species 0.000 claims 1
- 239000000412 dendrimer Substances 0.000 claims 1
- 229920000736 dendritic polymer Polymers 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000012800 visualization Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0495—Pretargeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10196092.0 | 2010-12-21 | ||
| EP10196092 | 2010-12-21 | ||
| PCT/IB2011/055730 WO2012085789A1 (en) | 2010-12-21 | 2011-12-16 | Agents for clearing biomolecules from circulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013133813A true RU2013133813A (ru) | 2015-01-27 |
Family
ID=43530614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013133813/15A RU2013133813A (ru) | 2010-12-21 | 2011-12-16 | Средства для выведения биомолекул из кровотока |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9427482B2 (enExample) |
| EP (1) | EP2654796A1 (enExample) |
| JP (1) | JP5992435B2 (enExample) |
| CN (1) | CN103328008B (enExample) |
| RU (1) | RU2013133813A (enExample) |
| WO (1) | WO2012085789A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2709666B1 (en) * | 2011-05-16 | 2021-07-14 | Koninklijke Philips N.V. | Bio-orthogonal drug activation |
| US10927139B2 (en) | 2012-11-22 | 2021-02-23 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| WO2014081300A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| WO2014081299A1 (en) * | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| US20150297741A1 (en) * | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| EP3010486B1 (en) | 2013-06-19 | 2023-11-22 | The Regents of The University of California | Chemical structures for localized delivery of therapeutic agents |
| AU2015229014B2 (en) | 2014-03-14 | 2019-07-25 | The Regents Of The University Of California | TCO conjugates and methods for delivery of therapeutic agents |
| WO2016025480A1 (en) | 2014-08-11 | 2016-02-18 | The General Hospital Corporation | Cyclooctenes for bioorthogonol reactions |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
| CN108135857A (zh) | 2015-09-10 | 2018-06-08 | 沙思奇公司 | 生物正交组合物 |
| US11617799B2 (en) * | 2016-06-27 | 2023-04-04 | Tagworks Pharmaceuticals B.V. | Cleavable tetrazine used in bio-orthogonal drug activation |
| US10222346B2 (en) * | 2017-01-09 | 2019-03-05 | National Research Council Of Canada | Decomposable S-tetrazine based polymers for single walled carbon nanotube applications |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| AU2018250312C1 (en) | 2017-04-07 | 2024-08-22 | Tambo, Inc. | Bioorthogonal compositions |
| ES3057687T3 (en) | 2017-07-06 | 2026-03-04 | Memorial Sloan Kettering Cancer Center | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy |
| EP3651741A4 (en) | 2017-07-14 | 2021-04-21 | The Penn State Research Foundation | COMPOSITIONS AND METHODS OF TARGETED DELIVERY OF A THERAPEUTIC AND / OR DIAGNOSTIC SPECIES |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| CN112088169A (zh) | 2018-03-12 | 2020-12-15 | 纪念斯隆凯特琳癌症中心 | 双特异性结合剂及其用途 |
| JP7337174B2 (ja) | 2018-09-18 | 2023-09-01 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 |
| WO2020247151A1 (en) * | 2019-06-05 | 2020-12-10 | Boston Scientific Scimed, Inc. | Click chemistry capturable platinum-based antineoplastic agents |
| WO2020256546A1 (en) | 2019-06-17 | 2020-12-24 | Tagworks Pharmaceuticals B.V. | Compounds for fast and efficient click release |
| CA3143924C (en) | 2019-06-17 | 2025-06-03 | Tagworks Pharmaceuticals B.V. | Agents that allow in vivo cleavage of markers linked to biomolecules |
| JP2023537066A (ja) | 2020-08-07 | 2023-08-30 | タンボ・インコーポレイテッド | トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用 |
| KR20250141267A (ko) * | 2023-02-15 | 2025-09-26 | 태그웍스 파마슈티컬스 비.브이. | 개선된 특성을 가지는 테트라진 |
| WO2025166249A1 (en) * | 2024-01-31 | 2025-08-07 | Oregon State University | Tetrazine amino acids and methods for their production and use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075010A (en) | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US5326856A (en) | 1992-04-09 | 1994-07-05 | Cytogen Corporation | Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding |
| US5624896A (en) | 1992-06-09 | 1997-04-29 | Neorx Corporation | Clearing agents useful in pretargeting methods |
| US5616690A (en) | 1992-06-09 | 1997-04-01 | Neorx Corporation | Hexose derivatized human serum albumin clearing agents |
| US20030129191A1 (en) | 1992-12-23 | 2003-07-10 | Neorx Corporation | Pretargeting methods and compounds |
| CA2178477A1 (en) | 1993-12-07 | 1995-06-15 | Louis J. Theodore | Pretargeting methods and compounds |
| JPH09506594A (ja) | 1993-12-07 | 1997-06-30 | ネオルクス コーポレーション | プレターゲティング方法及び化合物 |
| US5886143A (en) | 1994-12-07 | 1999-03-23 | Neorx Corporation | Hepatic-directed compounds and reagents for preparation thereof |
| US6908903B1 (en) | 1994-12-07 | 2005-06-21 | Aletheon Pharmaceuticals, Inc. | Cluster clearing agents |
| US6172045B1 (en) | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| JPH11507046A (ja) | 1995-06-07 | 1999-06-22 | イムノメディクス，インコーポレイテッド | 診断剤および治療剤の標的部位への改良された送達方法 |
| US7052872B1 (en) | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
| WO2006038184A2 (en) | 2004-10-07 | 2006-04-13 | Koninklijke Philips Electronics N.V. | Compounds, kits and methods for use in medical imaging |
| EP2026840A2 (en) | 2005-10-04 | 2009-02-25 | Koninklijke Philips Electronics N.V. | Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition |
| CN102271712B (zh) | 2008-10-31 | 2015-11-25 | 通用医疗公司 | 用于将物质递送至生物靶标的组合物和方法 |
| WO2010119389A2 (en) * | 2009-04-16 | 2010-10-21 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| US20120039803A1 (en) * | 2009-04-16 | 2012-02-16 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| CN108498873A (zh) | 2010-12-13 | 2018-09-07 | 生物模拟治疗有限责任公司 | 用于脊柱融合手术的组合物和方法 |
-
2011
- 2011-12-16 JP JP2013545584A patent/JP5992435B2/ja active Active
- 2011-12-16 US US13/994,783 patent/US9427482B2/en active Active
- 2011-12-16 EP EP11807788.2A patent/EP2654796A1/en not_active Withdrawn
- 2011-12-16 RU RU2013133813/15A patent/RU2013133813A/ru not_active Application Discontinuation
- 2011-12-16 WO PCT/IB2011/055730 patent/WO2012085789A1/en not_active Ceased
- 2011-12-16 CN CN201180061889.9A patent/CN103328008B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9427482B2 (en) | 2016-08-30 |
| CN103328008A (zh) | 2013-09-25 |
| WO2012085789A1 (en) | 2012-06-28 |
| JP5992435B2 (ja) | 2016-09-14 |
| US20130272959A1 (en) | 2013-10-17 |
| JP2014500307A (ja) | 2014-01-09 |
| EP2654796A1 (en) | 2013-10-30 |
| CN103328008B (zh) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013121799A (ru) | Набор для претаргетинга, способ и агенты, применяемые в нем | |
| ES2992544T3 (es) | Reactivos, composiciones y métodos para mejorar la viabilidad y función de células, tejidos y órganos | |
| RU2005138719A (ru) | Новые бисамидатные фосфонатные пролекарства | |
| ES3053660T3 (en) | Pharmaceutical combination comprising ponesimod and its use in the treatment of multiple sclerosis | |
| RU96107113A (ru) | C-22 циклические стабилизированные производные рапамицина | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| RU2011107752A (ru) | Агенты, связывающиеся с psma, и их применение | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2018520195A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| RU2015106915A (ru) | МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ | |
| RU2014128479A (ru) | Комбинированная терапия для стабильного и долговременного приживления трансплантата | |
| CA2455559A1 (en) | Methods to mobilize progenitor/stem cells | |
| JP2009504772A5 (enExample) | ||
| JP2018528942A5 (enExample) | ||
| AR010743A1 (es) | Compuestos de pirazol, utiles como inhibidores de la liberacion de acidos grasos mediada por la fosfolipasa a2 secretora no pancreatica humana.procedimientos para preparar dichos compuestos y composiciones farmaceuticas formuladas con dichos compuestos | |
| EA018983B1 (ru) | Способ усиления миграции гемопоэтических стволовых клеток, способ получения популяции указанных клеток и способы лечения с их использованием | |
| RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
| RU2014150569A (ru) | Конъюгат фотосенсибилизатора и хитозана и его применение | |
| JP2017537886A5 (enExample) | ||
| JP2020502131A5 (enExample) | ||
| CN114341148A (zh) | 抗衰老和抗炎前药及其使用方法 | |
| Zhou et al. | ROS-removing nano-medicine for navigating inflammatory microenvironment to enhance anti-epileptic therapy | |
| JP2012523432A5 (enExample) | ||
| CN120699073A (zh) | 烟酰胺单核苷酸衍生物及其在治疗和预防红细胞病症中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160428 |